November/December 2024

The Convergence of Nanotechnology and Retinal Disease

A look at the next generation of diagnostics and therapeutics.

Nalin J. Mehta, MD, MS, and Sachin N. Mehta, BA, BS

ASRS 2024: Looking Beyond Complement Inhibition

Could the next generation of geographic atrophy therapies be born of these novel strategies?

Scott Krzywonos

Geographic Atrophy Therapies to Watch

An update on complement inhibitors, gene and cell therapies, and novel approaches.

Rebecca Hepp, MA, Editor-in-Chief

The 2024 MEE Vitrectomy Course: A Training Camp for Fellows

First-year vitreoretinal fellows enjoyed 2 days of education and hands-on surgical training.

Melissa Yuan, MD; Elizabeth Rossin, MD, PhD; Nimesh A. Patel, MD; and John B. Miller, MD

A Closer Look at Ellipsoid Zone Attenuation

Could this structural finding, a newly-approved clinical trial endpoint, help us predict AMD progression? Here’s what we know so far.

Justis P. Ehlers, MD, and Charles C. Wykoff, MD, PhD, FASRS, FACS

A Sutureless Intrascleral Fixation Technique for the Carlevale IOL

No flaps, extra sclerotomies, or scleral sutures are necessary with this approach.

Eduardo Roditi, MD, and Burkhard Dick, MD, PhD, FEBOS-CR

Tenacity Pays Off

Allen C. Ho, MD, and Robert L. Avery, MD

Four Pearls for Managing Inferior Rhegmatogenous RD

These surgical insights can help trainees and young surgeons tackle challenging cases.

Luis Acabá-Berrocal, MD

Considerations for Combined Phacoemulsification Vitrectomy

All-in-one or staged approach? Here’s what we have learned in our practice.

James Dossett, MD; Christine Clavell, MD; Ami Patel, MD; and Ghassan Ghorayeb, MD, MBA

An Update on Sustained Drug Delivery in Retina

Unique ways to address treatment burden for patients with retinal conditions.

Deepak Sambhara, MD, and Marin Stowe, BS

Wet AMD Therapies in the Pipeline

A review of clinical trials investigating novel approaches to wet AMD in 2024.

Saumya M. Shah, MD, and Daniel Su, MD

The Therapeutic Landscape for Diabetic Eye Disease

Many novel approaches are chugging through the pipeline, with promising data from phase 2 and 3 trials.

Yingna Snowy Liu, MD; Shane Griffin, MD, MCR; and Chirag D. Jhaveri, MD

Progress in AI for Retinal Image Analysis

This technology is showing promise for disease risk stratification, diagnostic imaging, patient scheduling, and educational applications.

Sayena Jabbehdari, MD, MPH, MBA, and J. Fernando Arevalo, MD, PhD

Letter to the Editor: Hurdles to AI Adoption in Retina

Deep-learning algorithms have yet to meaningfully affect clinical practice—here’s why.

Hasenin Al-khersan, MD; Eliot Dow, MD, PHD; and Charles C. Wykoff, MD, PhD, FASRS, FACS

Top Discussions at ARDS 2024

This year’s panels focused on treating geographic atrophy, the latest surgical techniques, and rare conditions.

Hesham Gabr, MD

Multigenerational Autosomal Recessive Best Disease

Retinal findings raised suspicion for this inherited retinal disease, confirmed with genetic testing.

Sayena Jabbehdari, MD, MPH, MBA; Florin Grigorian, MD; and Michalis Georgiou, MD, PhD